- Price
- $78.09
- Day
- -1.19%
- Mkt Cap
- $3.36B
- 52W Range
- $53.85 – $91.53
- Volume
- 711.0K
- Beta
- 0.54
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Bank of New York Mellon Corp bought a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 114,458 shares of the company's stock, valued at approximately $7,204,000. Bank of New York Mellon
Read full article
Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no FDA-approved therapy Strengthens Tarsus' differentiated pipeline and leadership in eye care IRVINE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that it has completed its previously announced acquisition of Alkeus Pharmaceuticals, Inc., a privately held retinal disease-focused biotechnology company.
Read full article
Daily treatment with oral gildeuretinol met the primary endpoint and resulted in a statistically significant reduction in the growth rate of retinal atrophic lesions compared to untreated group. Gildeuretinol was well tolerated with no patient-reported events of dark adaptation delays or night blindness.
Read full article
IRVINE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8th H.C.
Read full article